Dolobid (Diflunisal) Patent Expiration, LOE Window & CMS Spending

Dolobid (Diflunisal) by Ina Pharmaceuti: Off-Patent Genericized (AB Competition), 3 AB generics, $8.2M 2024 CMS Part D & Medicaid spend, and $3,750 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIna Pharmaceuti
FDA Application & PathwayN018445 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$8.2M
2024 Medicare Part D Spend$671K
2024 Medicaid Spend$7.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,750 intro WAC)